These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 27522113)

  • 1. Pregnancy is more dangerous than the pill: A critical analysis of professional responses to the Yaz/Yasmin controversy.
    Geampana A
    Soc Sci Med; 2016 Oct; 166():9-16. PubMed ID: 27522113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "One Blood Clot Is One Too Many": Affected Vocal Users' Negative Perspectives on Controversial Oral Contraceptives.
    Geampana A
    Qual Health Res; 2019 Aug; 29(10):1519-1530. PubMed ID: 30957638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drospirenone-containing oral contraceptives and risk of adverse outcomes after myocardial infarction.
    Karabay CY; Kocabay G; Oduncu V; Kalayci A; Guler A; Karagöz A; Candan O; Basaran O; Zehir R; Izgi A; Esen AM; Kırma C
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):387-93. PubMed ID: 23361975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SOGC clinical practice guideline. No. 252, December 2010. Oral contraceptives and the risk of venous thromboembolism: an update.
    Reid R;
    J Obstet Gynaecol Can; 2010 Dec; 32(12):1192-1197. PubMed ID: 21176332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study].
    Fu Y; Mi W; Li L; Zhang H; Wang J; Cheng W; Sun L; Li L; Xie S; Zhang J
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):506-9. PubMed ID: 25327732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drospirenone/ethinyl estradiol.
    Rapkin AJ; Sorger SN; Winer SA
    Drugs Today (Barc); 2008 Feb; 44(2):133-45. PubMed ID: 18389090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill.
    Palacios S; Colli E; Regidor PA
    Acta Obstet Gynecol Scand; 2019 Dec; 98(12):1549-1557. PubMed ID: 31321765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 microg of ethinyl estradiol on the human endometrium.
    Lüdicke F; Johannisson E; Helmerhorst FM; Campana A; Foidart J; Heithecker R
    Fertil Steril; 2001 Jul; 76(1):102-7. PubMed ID: 11438327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YAZ and the novel progestin drospirenone.
    Mishell DR
    J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yasmin: the reason why.
    Thorneycroft IH
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of a new oral contraceptive containing drospirenone.
    Heinemann LA; Dinger J
    Drug Saf; 2004; 27(13):1001-18. PubMed ID: 15471507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethinyl estradiol/drospirenone (Yasmin): a newer oral contraceptive.
    Somma MA
    Am Fam Physician; 2004 May; 69(10):2425-6. PubMed ID: 15168965
    [No Abstract]   [Full Text] [Related]  

  • 14. [Efficacy and safety of drospirenone-ethinylestradiol on contraception in healthy Chinese women: a multicenter randomized controlled trial].
    Fan GS; Bian ML; Cheng LN; Cao XM; Huang ZR; Han ZY; Jing XP; Li J; Wu SY; Xiong CL; Xiong ZA; Yue TF
    Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):38-44. PubMed ID: 19563061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products.
    Sehovic N; Smith KP
    Ann Pharmacother; 2010 May; 44(5):898-903. PubMed ID: 20371756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double blind randomized control trial, comparing effect of drospirenone and gestodene to sexual desire and libido.
    Oranratanaphan S; Taneepanichskul S
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S17-22. PubMed ID: 17726807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive evaluation of Safyral(®) 2012.
    Nelson AL
    Womens Health (Lond); 2012 Nov; 8(6):619-33. PubMed ID: 23181528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
    Oelkers WH
    Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arterial thrombosis and drospirenone-containing pill (Yasmin). Is the pill to be absolutely avoided by women who smoke?
    Girolami A; Tezza F; Allemand E; Girolami B
    J Thromb Thrombolysis; 2008 Oct; 26(2):163-4. PubMed ID: 18157712
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.